Inhibiting the Deubiquitinase UCHL1 Reduces SARS-CoV-2 Viral Uptake by ACE2
American Journal of Respiratory Cell and Molecular Biology · 01.05.2023 · 68 (5) · 566-576
DOI: 10.1165/rcmb.2022-0331oc ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Respiratory Cell and Molecular Biology, online erschienen am 01.05.2023. Verfasst von Joseph S Bednash und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, and. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS, NCATS NIH HHS, NIAID NIH HHS.
Abstract (Originalsprache)
Coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), remains a significant public health burden with limited treatment options. Many β-coronaviruses, including SARS-CoV-2, gain entry to host cells through the interaction of SARS-CoV-2 spike protein with membrane-bound ACE2 (angiotensin-converting enzyme 2). Given its necessity for SARS-CoV-2 infection, ACE2 represents a potential therapeutic target in COVID-19. However, early attempts focusing on ACE2 in COVID-19 have not validated it as a druggable target nor identified other ACE2-related novel proteins for therapeutic intervention. Here, we identify a mechanism for ACE2 protein modulation by the deubiquitinase (DUB) enzyme UCHL1 (ubiquitin carboxyl-terminal hydrolase isozyme L1). ACE2 is constitutively ubiquitinated and degraded by the proteasome in lung epithelia. SARS-CoV-2 spike protein cellular internalization increased ACE2 protein abundance by decreasing its degradation. Using an siRNA library targeting 96 human DUBs, we identified UCHL1 as a putative regulator of ACE2 function as a viral receptor. Overexpressed UCHL1 preserved ACE2 protein abundance, whereas silencing of the DUB in cells destabilized ACE2 through increased polyubiquitination. A commercially available small molecule inhibitor of UCHL1 DUB activity decreased ACE2 protein concentrations coupled with inhibition of SARS-CoV-2 infection in epithelial cells. These findings describe a unique pathway of ACE2 regulation uncovering UCHL1 as a potential therapeutic target to modulate COVID-19 viral entry as a platform for future small molecule design and testing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, and.
- Department of Microbial Infection and Immunity, The Ohio State University, Columbus, Ohio.
ORCID-Profile: Joseph S Bednash, Jacob S Yount, Rama K Mallampalli
Förderung
- NHLBI NIH HHS
- NCATS NIH HHS
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
- National Heart, Lung, and Blood Institute
- National Center for Advancing Translational Sciences
Zitieren
APA
Bednash, J. S., Johns, F., Farkas, D., Elhance, A., Adair, J., Cress, K., Yount, J. S., Kenney, A. D., Londino, J. D., & Mallampalli, R. K. (2023). Inhibiting the Deubiquitinase UCHL1 Reduces SARS-CoV-2 Viral Uptake by ACE2. American Journal of Respiratory Cell and Molecular Biology, 68(5), 566-576. https://doi.org/10.1165/rcmb.2022-0331oc
Vancouver
Bednash JS, Johns F, Farkas D, Elhance A, Adair J, Cress K, et al. Inhibiting the Deubiquitinase UCHL1 Reduces SARS-CoV-2 Viral Uptake by ACE2. American Journal of Respiratory Cell and Molecular Biology. 2023;68(5):566-576. doi:10.1165/rcmb.2022-0331oc
BibTeX
@article{Bednash2023,
author = {Bednash, Joseph S and Johns, Finny and Farkas, Daniela and Elhance, Ajit and Adair, Jessica and Cress, Kirstin and Yount, Jacob S and Kenney, Adam D and Londino, James D and Mallampalli, Rama K},
title = {Inhibiting the Deubiquitinase UCHL1 Reduces SARS-CoV-2 Viral Uptake by ACE2},
journal = {American Journal of Respiratory Cell and Molecular Biology},
year = {2023},
volume = {68},
number = {5},
pages = {566--576},
doi = {10.1165/rcmb.2022-0331oc}
}
EUVIMED